Fig. 1

Identification and characterization of circEAF2 in Epstein-Barr virus-positive diffuse large B cell lymphoma. A Volcano plot showed the differential expressed circRNAs of EBV + DLBCL (N = 8), as compared to EBV-DLBCL (N = 4), analyzed by circRNA high-throughput sequencing. B Relative expression of circEAF2 from 7 B-lymphoma cell lines and 54 DLBCL tumor samples. Results on tumor samples was further transformed by LogE. C Relative expression of circEAF2 (line graph) and EBV DNA copy number (bar graph) in SU-DHL-4 and OCI-LY-10 cells during acute EBV infection or long-term EBV infection, as compared to those without EBV infection (negative control, NC). D Schematic diagram showed the genomic locus of circEAF2 in EAF2 gene. Sequencing results showed the back-splice junction sequences of circEAF2. Arrows represented divergent primers that bind to the back-splicing region of circEAF2. E Left panel: The expression of circEAF2 and mRNA EAF2 after RNase R treatment. Right panel: The expression changes of circEAF2 and mRNA EAF2 at the corresponding time points after treatment with amphotericin D. Results are presented as the RNA expression level relative to those without RNase R or amphotericin D treatment (negative control, NC). F qRT-PCR assay with divergent or convergent primers indicated the existence of circEAF2 or mRNA EAF2, respectively, using cDNA and gDNA as templates. EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; circRNA, Circular RNA; EBV+, EBV positivity; EBV-, EBV negativity; R, Reverse primer; F, Forward primer; gDNA, Genomic DNA; cDNA, Complement deoxyrubonucleic acid. Con, control group. Data were shown as the mean ± S.D. of three experiments